Incidence of chemotherapy-induced nausea and vomiting (CINV) after highly and moderately emetogenic therapy in the era of NK-1 inhibitors - perception versus reality

被引：0
|
作者：
Perez-Altozano, J. [1 ]
Majem, M. [1 ]
Calvo, N. [1 ]
Moreno, E. [1 ]
Feliu, A. [1 ]
Gich, I. [1 ]
Mangues, A. [1 ]
Barnadas, A. [1 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Barcelona, Spain
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)70629-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：184 / 184
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in non-anthracycline/cyclophosphamide (AC)-based moderately emetogenic therapy (MEC).
    Powers, Daniel
    Hesketh, Paul Joseph
    Schwartzberg, Lee Steven
    Modiano, Manuel R.
    Arora, Sujata
    Schnadig, Ian D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29)
  • [42] Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC)
    Herrstedt, J.
    Grunberg, S.
    Rolski, J.
    Bandekar, R. R.
    Guckert, M. E.
    Camlett, I.
    Russo, M. W.
    Strausz, J.
    Aziz, Z.
    Thorn, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] Antiemetic use and chemotherapy induced nausea and vomiting related hospitalization costs after highly or moderately emetogenic chemotherapy
    Nelson, Winnie W.
    Vaidya, Varun
    Scott, Jeffery A.
    Wang, Brandon
    Lambert, Hunter
    Holmes, Benjamin
    Bailey, William L.
    FUTURE ONCOLOGY, 2023, 19 (01) : 29 - 36
  • [44] APREPITANT IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY OR HIGHLY EMETOGENIC CHEMOTHERAPIES IN PATIENTS WITH GASTROINTESTINAL CANCER
    Boice, J.
    Brown, C.
    Taylor, A.
    Hardwick, J.
    Carides, A.
    ANNALS OF ONCOLOGY, 2009, 20 : 69 - 69
  • [45] Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy
    Warr, DG
    Hesketh, PJ
    Gralla, RJ
    Muss, HB
    Herrstedt, J
    Eisenberg, PD
    Raftopoulos, H
    Grunberg, SM
    Gabriel, M
    Rodgers, A
    Bohidar, N
    Klinger, G
    Hustad, CM
    Horgan, KJ
    Skobieranda, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) : 2822 - 2830
  • [46] An oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy
    Pendergrass, K
    Hargreaves, R
    Petty, KJ
    Carides, AD
    Evans, JK
    Horgan, KJ
    DRUGS OF TODAY, 2004, 40 (10) : 853 - 863
  • [47] Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic (MEC) or highly emetogenic (HEC) chemotherapies in patients with lung cancer
    Rapoport, B.
    Boice, J. A.
    Brown, C.
    Street, J. C.
    Hardwick, J. S.
    Carides, A. D.
    Gralla, R. J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 519 - 520
  • [48] Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study
    Tan, M
    Xu, R
    Seth, R
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (06) : 879 - 882
  • [49] Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients
    Ronald Chow
    Leonard Chiu
    Jørn Herrstedt
    Matti Aapro
    Michael Lock
    Carlo DeAngelis
    Rudolph M. Navari
    Supportive Care in Cancer, 2021, 29 : 4269 - 4275
  • [50] A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
    Zelek, Laurent
    Debourdeau, Philippe
    Bourgeois, Hugues
    Wagner, Jean Philippe
    Brocard, Fabien
    Lefeuvre-Plesse, Claudia
    Chauffert, Bruno
    Leheurteur, Marianne
    Bachet, Jean-Baptiste
    Simon, Helene
    Mayeur, Didier
    Scotte, Florian
    ONCOLOGIST, 2021, 26 (10): : E1870 - E1879
12345